Novel Composition

Abstract

Novel combined vaccine compositions are provided, comprising a hepatitis B viral antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivat3ed attenuated virus, a herpes simplex viral antigen, a VZV antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

1 - 21 . (canceled) 
     
     
         22 . A vaccine composition comprising:
 (a) a hepatitis B viral antigen; and   (b) a  Heamophilus influenza  B Protein D-HPV 16 E7 fusion protein;   in conjunction with an adjuvant which is a preferential stimulator of TH1 cell response wherein the vaccine composition stimulates a TH1-type immune response.   
     
     
         23 . A vaccine composition according to  claim 22  which additionally comprises a carrier. 
     
     
         24 . A vaccine composition according to  claim 22  in which the preferential stimulator of TH1-cell response is selected from the group of adjuvants comprising: 3D-MPL, 3D-MPL wherein the size of the particles of 3D-MPL is preferably about or less than 100 nm, QS21, a mixture of QS21 and cholesterol, and a CpG oligonucleotide. 
     
     
         25 . A vaccine composition according to  claim 24  in which the preferential stimulator of TH1-cell response is 3D-MPL. 
     
     
         26 . A vaccine composition according to  claim 22  in which the Hepatitis B antigen is hepatitis B surface antigen. 
     
     
         27 . A vaccine composition consisting essentially of:
 (a) a hepatitis B viral antigen;   (b) a  Heamophilus influenza  B Protein D-HPV 16 E7 fusion protein   in conjunction with an adjuvant which is a preferential stimulator of TH1 cell response wherein the vaccine composition stimulates a TH1-type immune response.   
     
     
         28 . A vaccine composition consisting of:
 (a) a hepatitis B viral antigen;   (b) a  Heamophilus influenza  B Protein D-HPV 16 E7 fusion protein; and   (c) an aqueous carrier   in conjunction with an adjuvant which is a preferential stimulator of TH1 cell response wherein the vaccine composition stimulates a TH1-type immune response.